Treato: Healthcare Insights Company Examines Patients’ Attitudes Towards Costs Related to Xtandi, Ibrance and Xarelto

Treato: Healthcare Insights Company Examines Patients’ Attitudes Towards Costs Related to Xtandi, Ibrance and Xarelto

Today Treato, the single largest source of online consumer insights on healthcare, announced the results of an analysis that indicates patients feel entitled to a drug discount program when prescribed a costly new drug and didn’t express gratitude towards the manufacturer covering the cost.  The Big Data analysis examined how patients were discussing costs related to Xtandi (prostate cancer) $9,682.80 for a 30 day treatment of the recommended four 40mg pills each day, Ibrance (breast cancer) $10,679.94 for the recommended treatment of one 125mg pill once a day for 21 days followed by seven days of no treatment and Xarelto (blood thinner), $360.11 for a 30 day treatment of one 20mg pill each day*.  These three drugs were selected for analysis since they have been making headlines recently for their significant costs to patients without insurance compared to other available older forms of therapy. 

Read more

Topics: News

Posted by

Truveris Team